Exousia Bio (LMMY) Stock Overview
A biotechnology company, designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LMMY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Exousia Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.44 |
| 52 Week High | US$0.94 |
| 52 Week Low | US$0.17 |
| Beta | 0 |
| 1 Month Change | 21.69% |
| 3 Month Change | 9.53% |
| 1 Year Change | 68.50% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 119.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| LMMY | US Entertainment | US Market | |
|---|---|---|---|
| 7D | 0% | 3.3% | 1.6% |
| 1Y | 68.5% | -22.6% | 18.6% |
Return vs Industry: LMMY exceeded the US Entertainment industry which returned -22.6% over the past year.
Return vs Market: LMMY exceeded the US Market which returned 18.6% over the past year.
Price Volatility
| LMMY volatility | |
|---|---|
| LMMY Average Weekly Movement | n/a |
| Entertainment Industry Average Movement | 8.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LMMY's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine LMMY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 2 | Matthew Dwyer | exousiabio.com |
Exousia Bio, Inc., a biotechnology company, designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company’s platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026.
Exousia Bio, Inc. Fundamentals Summary
| LMMY fundamental statistics | |
|---|---|
| Market cap | US$23.00m |
| Earnings (TTM) | -US$80.16k |
| Revenue (TTM) | n/a |
Is LMMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LMMY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$69.36k |
| Gross Profit | -US$69.36k |
| Other Expenses | US$10.80k |
| Earnings | -US$80.16k |
Last Reported Earnings
Feb 28, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0015 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LMMY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/04 22:45 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2026/02/28 |
| Annual Earnings | 2025/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exousia Bio, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.